Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 15, 2022 08:15 ET | Source: RP Management, LLC

Royalty Pharma Declares Third Quarter 2022 Dividend

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A...
July 14, 2022 08:30 ET | Source: RP Management, LLC

Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022

NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 before the...
July 13, 2022 16:25 ET | Source: RP Management, LLC

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

Further diversifies Royalty Pharma’s portfolio with market-leading respiratory therapyExpected to significantly add to long-term Adjusted Cash Receipts growth(1) (non-GAAP) NEW YORK, July 13, 2022 ...
June 30, 2022 07:31 ET | Source: RP Management, LLC

Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June ...
May 23, 2022 08:30 ET | Source: RP Management, LLC

Royalty Pharma to Present at the UBS Global Healthcare Conference 2022

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m....
May 17, 2022 07:00 ET | Source: RP Management, LLC

Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders

New capital deployment target of $10-12 billion over the next five yearsOutlook for 2020-2025 Adjusted Cash Receipts (1) (non-GAAP) CAGR raised to 11-14%Adjusted Cash Receipts (1) (non-GAAP) expected...
May 05, 2022 07:00 ET | Source: RP Management, LLC

Royalty Pharma Reports First Quarter 2022 Results

Net cash provided by operating activities (GAAP) of $460 million; Adjusted Cash Receipts(1) (non-GAAP) of $605 million Announced transactions of up to $450 million in Q1 20222022 guidance reaffirmed:...
April 18, 2022 08:00 ET | Source: RP Management, LLC

Royalty Pharma Declares Second Quarter 2022 Dividend

NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A...
April 13, 2022 08:00 ET | Source: RP Management, LLC

Royalty Pharma to Announce First Quarter 2022 Financial Results on May 5, 2022

NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 before the U.S....
March 03, 2022 08:30 ET | Source: RP Management, LLC

Royalty Pharma to Present at Cowen's 42nd Annual Health Care Conference

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on...